%0 Journal Article
%T Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced nonŠ\small cell lung cancer
%A Akihiro Yoshimura
%A Junji Uchino
%A Keiko Tanimura
%A Koichi Takayama
%A Nobuyo Tamiya
%A Tadaaki Yamada
%A Takayuki Takeda
%A Yoshiko Kaneko
%A Yuki Katayama
%A Yusuke Chihara
%J Archive of "Thoracic Cancer".
%D 2019
%R 10.1111/1759-7714.12969
%X Cancer immunotherapy is under development as a promising alternative strategy for treating advanced nonŠ\small cell lung cancer (NSCLC). However, the development of novel biomarkers to optimize the use of immune checkpoint inhibitors (ICIs) is still ongoing. Gut microbiota are known to regulate a host's immunity and are associated with the response to ICIs in melanoma. Therefore, we analyzed the association between ICI treatment efficacy and bowel movement condition in patients with NSCLC
%K Biomarker
%K bowel movement condition
%K immunotherapy
%K nonŠ\small cell lung cancer
%K retrospective study
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397896/